Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head‐and‐neck cancer

BACKGROUND: Agents targeting the programmed cell death‐1 pathway have demonstrated encouraging activity across multiple solid tumor types. The dose expansion phase of this phase I study evaluated the safety, tolerability, and antitumor activity of durvalumab monotherapy, and durvalumab plus tremelim...

Descripción completa

Detalles Bibliográficos
Autores principales: Doki, Yuichiro, Ueno, Makoto, Hsu, Chih‐Hung, Oh, Do‐Youn, Park, Keunchil, Yamamoto, Noboru, Ioka, Tatsuya, Hara, Hiroki, Hayama, Manabu, Nii, Masahiro, Komuro, Keiko, Sugimoto, Mariko, Tahara, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249982/
https://www.ncbi.nlm.nih.gov/pubmed/35611499
http://dx.doi.org/10.1002/cam4.4593

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249982/
https://www.ncbi.nlm.nih.gov/pubmed/35611499
http://dx.doi.org/10.1002/cam4.4593

Ejemplares similares